ASPI Stock Forecast & Price Target

ASP Isotopes Inc. has demonstrated strong revenue growth, with approximately $4.9 million reported, reflecting a 345.5% year-over-year increase and a 308.3% sequential growth, significantly surpassing prior estimates. Management anticipates further expansion driven by increased volume and deliveries of SPECT doses, along with future offerings such as PET services projected to commence in 2027. Additionally, the company's strategic alignments with emerging markets in helium and advanced isotopes suggest substantial long-term revenue opportunities, particularly in sectors like semiconductors and next-generation nuclear technology.

ASP Isotopes Inc. has reported a significant decline in gross margin, dropping to approximately 8.7%, which fell short of expectations and decreased from 27.0% year-over-year and 47.7% sequentially. The company also recorded a net loss of $12.1 million for the quarter, worsening from a net loss of $7.3 million in the previous year, highlighting deteriorating financial health. Further compounding these issues, ASP Isotopes faces delays in revenue generation due to postponed timelines for commercial isotope deliveries and increasing operational risks associated with liquidity constraints and a volatile economic environment.